Compare Stocks: GHSI, CTXR, QNRX, and SCNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.60 +2.2%	$0.59	$0.47 ▼ $2.19	$16.13M	1	674,410 shs	310,466 shs
GHSI Guardion Health Sciences	$3.22	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	N/A
QNRX Quoin Pharmaceuticals	$7.15 -1.5%	$5.06	$3.25 ▼ $41.80	$14.58M	1.51	1.66 million shs	196,026 shs
SCNX Scienture	$0.36 -2.5%	$0.39	$0.24 ▼ $2.60	$15.32M	3.25	3.48 million shs	210,964 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+2.18%	+5.52%	-11.99%	+8.61%	-50.78%
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
QNRX Quoin Pharmaceuticals	-1.52%	+9.83%	+49.27%	+41.30%	-6.72%
SCNX Scienture	-2.49%	-0.90%	-4.31%	+3.09%	-59.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.60 +2.2%	$0.59	$0.47 ▼ $2.19	$16.13M	1	674,410 shs	310,466 shs
GHSI Guardion Health Sciences	$3.22	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	N/A
QNRX Quoin Pharmaceuticals	$7.15 -1.5%	$5.06	$3.25 ▼ $41.80	$14.58M	1.51	1.66 million shs	196,026 shs
SCNX Scienture	$0.36 -2.5%	$0.39	$0.24 ▼ $2.60	$15.32M	3.25	3.48 million shs	210,964 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+2.18%	+5.52%	-11.99%	+8.61%	-50.78%
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
QNRX Quoin Pharmaceuticals	-1.52%	+9.83%	+49.27%	+41.30%	-6.72%
SCNX Scienture	-2.49%	-0.90%	-4.31%	+3.09%	-59.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	732.64% Upside
GHSI Guardion Health Sciences	0.00	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	2.00	Hold	N/A	N/A
SCNX Scienture	2.00	Hold	$1.50	312.43% Upside

Current Analyst Ratings Breakdown

Latest GHSI, CTXR, QNRX, and SCNX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	QNRX Quoin Pharmaceuticals	ThinkEquity Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
GHSI Guardion Health Sciences	$12.25M	0.35	$0.14 per share	23.15	$6.39 per share	0.50
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A
SCNX Scienture	$430K	34.73	N/A	N/A	$1.73 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
GHSI Guardion Health Sciences	$160K	$4.87	0.66	N/A	N/A	22.79%	-73.69%	-48.17%	N/A
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)

Latest GHSI, CTXR, QNRX, and SCNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHSI Guardion Health Sciences	$5.00	155.28%	N/A	102.67%	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
GHSI Guardion Health Sciences	N/A	16.68	16.59
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
GHSI Guardion Health Sciences	20.21%
QNRX Quoin Pharmaceuticals	8.63%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	4.99%
GHSI Guardion Health Sciences	1.32%
QNRX Quoin Pharmaceuticals	11.17%
SCNX Scienture	21.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
GHSI Guardion Health Sciences	10	1.35 million	1.33 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	2.01 million	1.78 million	Not Optionable
SCNX Scienture	N/A	41.06 million	32.28 million	N/A

GHSI, CTXR, QNRX, and SCNX Headlines

Recent News About These Companies

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

SCNX Share News Today

July 4, 2026 | uk.investing.com

Scienture Holdings (SCNX) Stock Forecast & Price Target

June 25, 2026 | investing.com

Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga

June 24, 2026 | benzinga.com

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

June 18, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

June 17, 2026 | theglobeandmail.com

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

June 9, 2026 | globenewswire.com

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

June 4, 2026 | accessnewswire.comA

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

June 2, 2026 | globenewswire.com

Scienture Holdings Announces CFO Resignation, Names Interim Successor

May 29, 2026 | tipranks.com

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026 | globenewswire.com

Scienture Holdings Inc SCNX

May 12, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHSI, CTXR, QNRX, and SCNX Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$0.60 +0.01 (+2.18%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+2.25%)

As of 05:25 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Quoin Pharmaceuticals NASDAQ:QNRX

$7.15 -0.11 (-1.52%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$6.94 -0.21 (-2.87%)

As of 05:56 AM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Scienture NASDAQ:SCNX

$0.36 -0.01 (-2.49%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.40 +0.03 (+8.88%)

As of 06:28 AM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHSI, CTXR, QNRX, and SCNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHSI, CTXR, QNRX, and SCNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHSI, CTXR, QNRX, and SCNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHSI, CTXR, QNRX, and SCNX Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Guardion Health Sciences NASDAQ:GHSI

Quoin Pharmaceuticals NASDAQ:QNRX

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHSI, CTXR, QNRX, and SCNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHSI, CTXR, QNRX, and SCNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHSI, CTXR, QNRX, and SCNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHSI, CTXR, QNRX, and SCNX Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Guardion Health Sciences NASDAQ:GHSI

Quoin Pharmaceuticals NASDAQ:QNRX

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools